Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients

References

• Lysaght MJ. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol. 2002;13:37–40.
   PubMed Web of Science ®Google Scholar
• Wong G, Howard K, Chapman JR, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying age and comorbidities. Plos One. 2012;7:e29591.
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report. Am J Transplant. 2015;15(S2):1–34.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363:1451–1462.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, et al. DIabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185.
   PubMed Web of Science ®Google Scholar
• Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496–506.
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;352:2715–2729.
   Web of Science ®Google Scholar
• Pasual M, Theruvath T, Kawai T, et al. Strategies to improve long term outcomes after kidney transplantation. N Engl J Med. 2002;346:580–590.
   PubMed Web of Science ®Google Scholar
• Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2009;87:591–605.
   PubMed Web of Science ®Google Scholar
• Kamar N, Del Bello A, Belliere J, et al. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. Transplant Int. 2015. DOI:10.1111/tri.12515.
   Web of Science ®Google Scholar
• Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014;10:14–24.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Sharpe AH, Hafler DA. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol. 1999;11:677–683.
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethaly in mice deficient in CTLA-4. Science. 1995;270:985–988.
   PubMed Web of Science ®Google Scholar
• Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmunedisease therapy. Cell. 1995;80:707–718.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995;181:1145–1155.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353:770–781.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–546.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplant from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547–557.
   PubMed Web of Science ®Google Scholar
• Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90:1521–1527.
   PubMed Web of Science ®Google Scholar
• Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86 receptor saturation. Transplantation. 2009;87:926–933.
   PubMed Web of Science ®Google Scholar
• Shen J, Townsend R, You X, et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Investig. 2014;34:117–126.
   PubMed Web of Science ®Google Scholar
• Ferguson R, Grinyo J, Vicenti F, et al. Immunosuppression with belatacept based corticosteroid avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66–76.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21:1587–1596.
   PubMed Web of Science ®Google Scholar
• Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014. DOI:10.1002/14651858.CD010699.pub2.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Vincenti F, Grinyo J, et al. Long term belatacept exposure maintains efficacy and safety at 5 years: results from the long term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–2883.
   PubMed Web of Science ®Google Scholar
• Charpentier B, Medina Pestana JO, Del C Rial M, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2014;13:2884–2891.
   Web of Science ®Google Scholar
• Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528–1535.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mayerhoffer S, Berlakovich GA, et al. Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. Transplant Int. 2015;28:820–827.
   PubMed Web of Science ®Google Scholar
• Schnitzler MA, Lentine KL, Axelrod D, et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Transplantation. 2012;93:172–181.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept versus cyclosporine based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol. 2011;6:2696–2704.
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91:976–983.
   PubMed Web of Science ®Google Scholar
• Seibert FS, Steltzer J, Melilli E, et al. Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation. Clin Transplant. 2014;28:1004–1009.
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006;113:1213–1225.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Messari P, Duro Garcia V, et al. Switching from calcineurin inhibitor based regimens to a belatacept based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6:430–439.
   PubMed Web of Science ®Google Scholar
• Grinyo J, Alberu J, Contieri FL, et al. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int. 2012;25:1059–1064.
   PubMed Web of Science ®Google Scholar
• Kamar N, Rial M, Alberu J, et al. 3-Year outcomes after switching to belatacept from a CNI in stable kidney transplant recipients [abstract]. Transplant Int. 2013;26(S2):44. Abstract n64.
   Google Scholar
• Pallet N, Legendre C. Adverses events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12:177–186.
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869–1875.
   PubMed Web of Science ®Google Scholar
• Belliere J, Guilbeau-Frugier C, Del Bello A, et al. Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate. Case Rep Transplant. 2014. DOI:10.1155/2014/190516.
   PubMedGoogle Scholar
• Vincenti F, Larsen CP, Alberu J, et al. 3 years outcome from BENEFIT: a randomized active controlled parallel group study in adult kidney transplant recipients. Am J Transplant. 2012;12:210–217.
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12:630–639.
   PubMed Web of Science ®Google Scholar
• Haidinger M, Hecking M, Memarsadeghi M, et al. Late onset pneumocystis pneumonia in renaltransplantation after long term immunosuppression with belatacept. Transplant Infec Dis. 2009;11:171–174.
   PubMed Web of Science ®Google Scholar
• Bassil N, Rostaing L, Mengelle C, et al. Prospective monitoring of cytomegalovirus, Epstein–Barr virus, BK-virus, and JC virus infections on belatacept therapy after a kidney transplant. Exp Clin Transplant. 2014;12:2012–2019.
   Google Scholar
• Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1 positive proteinuric kidney disease. N Engl J Med. 2013;369:2416–2423.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept) a high-affinity variant of CTLA-4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–453.
   PubMed Web of Science ®Google Scholar
• Grellier J, Del Bello A, Milongo D, et al. Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transplant Int. 2015. DOI:10.1111/tri.12574.
   PubMed Web of Science ®Google Scholar
• Garin EH, Reiser J, Cara-Fuentes G, et al. Case series: CTLA-4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol. 2015;30:469–477.
   PubMed Web of Science ®Google Scholar
• Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370:1263–1264.
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Bitter J, Dørje C, et al. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation. 2009;87:1901–1903.
   PubMed Web of Science ®Google Scholar
• Gaynor JJ, Ciancio G, Guerra G, et al. Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observationnal study. Transplantation. 2014;97:925–933.
   PubMed Web of Science ®Google Scholar
• Gupta G, Regmi A, Kumar D, et al. Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction. Am J Transplant. 2015. DOI:10.1111/ajt.13322.
   Web of Science ®Google Scholar
• Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant. 2014;14:1142–1151.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001;72:377–384.
   PubMed Web of Science ®Google Scholar
• Badell JR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant. 2012;12:126–135.
   PubMed Web of Science ®Google Scholar
• Pinelli DF, Wagener ME, Liu D, et al. An anti-CD154 domain antibody prolongs graft survival and induces FoxP3+ iTreg in the absence and presence of CTLA-4 Ig. Am J Transplant. 2013;13:3021–3030.
   PubMed Web of Science ®Google Scholar
• Muduma G, Shaw J, Hart WM, et al. Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Prefer Adherence. 2014;8:1537–1546.
   PubMed Web of Science ®Google Scholar